Source published November 4, 2026: Clinical TMS Society statement on considering transcranial magnetic stimulation for depression during pregnancy.
What the statement says The Clinical TMS Society says pregnant patients should not be categorically excluded from TMS when depression treatment is being considered. Its statement asks clinicians and patients to weigh the risks of treatment against the risks of untreated illness and recommends collaboration with obstetric care. This is a professional-society position, not a universal recommendation for every patient.
What supports the position The statement cites one randomized trial along with open-label studies, systematic reviews, meta-analyses and case reports. It says response and remission patterns have been broadly similar to those reported in nonpregnant adults and describes the published safety experience as reassuring. The pregnancy-specific evidence base is still much smaller than the general-adult depression evidence base, so absence of a reported problem does not prove zero risk.
Practical safety points Headache and local discomfort remain common TMS effects. The statement notes that seizure is rare with TMS and that no seizure has been reported in the pregnancy literature it reviewed. It also highlights positioning in advanced pregnancy because lying reclined or supine can contribute to low blood pressure from uterine compression of major vessels. The cited randomized evidence did not find worse preterm-birth or selected neonatal outcomes than sham, but the available studies are not large enough to rule out uncommon harms.
Why coordinated care matters Depression during pregnancy can affect both the pregnant person and child, and treatment choices may involve medication, psychotherapy, TMS or other supports. A useful discussion includes illness severity, prior response, alternatives, pregnancy-related conditions, clinician qualifications, the proposed protocol, monitoring and what would trigger a change in plan. TMS should not be started, stopped or substituted for other care based on a web summary.
The evidence boundary The statement supports consideration, not a claim that TMS is best for all pregnant patients or risk free. Pregnancy-specific trials remain limited, and published reports may not capture rare outcomes or every clinical circumstance. Individual decisions belong with qualified mental-health and obstetric professionals using current guidance and the patient's full history.
Disclosure This is coverage of a professional-society statement, not medical advice or a treatment recommendation. Prepared with AI assistance; the statement and its cited reference list were checked November 5, 2026. The image is an AI-generated conceptual consultation scene with fictional people. It does not depict a real patient, clinic, procedure, device or outcome.